- ~90,000 U.S. and EU Patients Initiated
Treatment on Sovaldi or Harvoni -
- Product Sales of $7.4 billion -
- Non-GAAP EPS of $2.94 per share -
- Revised 2015 Full Year Guidance -
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results
of operations for the first quarter ended March 31, 2015. The
financial results that follow represent a year over year comparison
of first quarter 2015 to the first quarter 2014. Total revenues
were $7.6 billion in 2015 compared to $5.0 billion in 2014. Product
sales were $7.4 billion in 2015 compared to $4.9 billion in 2014.
Net income was $4.3 billion, or $2.76 per diluted share in 2015
compared to $2.2 billion or $1.33 per diluted share in 2014.
Non-GAAP net income, which excludes amounts related to acquisition,
restructuring, stock-based compensation and other, was $4.6
billion, or $2.94 per diluted share in 2015 compared to $2.5
billion or $1.48 per diluted share in 2014.
Three Months Ended March 31, (In millions,
except per share amounts) 2015 2014
Product sales $ 7,405 $ 4,871 Royalty, contract and other revenues
189 128 Total revenues $ 7,594 $ 4,999 Net
income attributable to Gilead $ 4,333 $ 2,227 Non-GAAP net income
attributable to Gilead $ 4,604 $ 2,488 Diluted EPS $ 2.76 $
1.33 Non-GAAP diluted EPS $ 2.94 $ 1.48
Product Sales
Total product sales for the first quarter of 2015 were $7.4
billion compared to $4.9 billion for the first quarter of 2014. In
the first quarter, product sales in the U.S. were $5.2 billion
compared to $3.6 billion for the first quarter of 2014, and in
Europe, product sales for the first quarter of 2015 were $1.8
billion compared to $1.0 billion for the same period in 2014.
Antiviral Product Sales
Antiviral product sales increased to $7.0 billion for the first
quarter of 2015, up from $4.5 billion for the first quarter of 2014
primarily due to sales of Harvoni® (ledipasvir 90 mg/sofosbuvir 400
mg), which was approved in the U.S. and Europe in the fourth
quarter of 2014, partially offset by a decrease in sales of
Sovaldi® (sofosbuvir).
Other Product Sales
Other product sales, which include Letairis®, Ranexa® and
AmBisome®, were $417 million for the first quarter of 2015 compared
to $362 million for the first quarter of 2014.
Operating Expenses
During the first quarter of 2015, compared to the same period in
2014:
- Non-GAAP research and development
(R&D) expenses increased primarily due to the continued
progression and expansion of Gilead's clinical studies,
particularly phase 3 studies in the liver disease and oncology
areas.
- Non-GAAP selling, general and
administrative (SG&A) expenses increased primarily due to
growth in our business including commercial expansion for our
hepatitis C virus (HCV) products.
Three Months Ended March 31, (In
millions) 2015 2014 Non-GAAP research and
development expenses $ 651 $ 558 Non-GAAP selling, general and
administrative expenses $ 600 $ 500
Note: Non-GAAP R&D and SG&A expenses exclude amounts
related to acquisition, restructuring, stock-based compensation and
other.
Cash, Cash Equivalents and Marketable
Securities
As of March 31, 2015, Gilead had $14.5 billion of cash, cash
equivalents and marketable securities compared to $11.7 billion as
of December 31, 2014. During the first quarter of 2015, Gilead
generated $5.7 billion in operating cash flow and utilized $3.0
billion to repurchase shares, which completes our May 2014 stock
repurchase program.
Revised 2015 Full Year
Guidance
Gilead updated its full year 2015 guidance, which it initially
provided on February 3, 2015.
(In millions, except percentages and per share amounts)
Initially ProvidedFebruary 3,
2015
UpdatedApril 30, 2015
Net Product Sales $26,000 - $27,000 $28,000 - $29,000
Non-GAAP* Product Gross Margin 87% - 90% 87% - 90% R&D $3,000 -
$3,300 $3,000 - $3,300 SG&A $3,000 - $3,300 $3,000 - $3,300
Effective Tax Rate 18.0% - 20.0% 18.0% - 20.0% Diluted EPS
Impact of Acquisition-Related, Restructuring, Stock-Based
Compensation Expenses and Other $0.82 - $0.87 $0.82 - $0.87
* Non-GAAP product gross margin, R&D and SG&A expenses and
effective tax rate exclude amounts related to acquisition,
restructuring, stock-based compensation and other.
Product & Pipeline Updates
Announced by Gilead During the First Quarter of 2015
Include:
Antiviral Program
- Announced that the Japanese Ministry of
Health, Labour and Welfare approved Sovaldi for the suppression of
viremia in patients with genotype 2 chronic HCV infection with or
without compensated cirrhosis. Sovaldi is indicated for use in
combination with ribavirin (RBV) for 12 weeks. Sovaldi (in
combination with RBV) is the first all-oral, interferon-free
treatment regimen for genotype 2 HCV infection.
- Presentation of data at the 22nd
Conference on Retroviruses and Opportunistic Infections included
announcement of:
- Positive results from a Phase 3
clinical trial evaluating the once-daily single tablet regimen
Harvoni for the treatment of genotypes 1 or 4 chronic HCV infection
among patients co-infected with HIV. In the trial, 96 percent of
HCV patients achieved a sustained virologic response 12 weeks after
completing therapy (SVR12). Patients who achieve SVR12 are
considered cured of HCV infection.
- Positive 48-week results from two Phase
3 studies (Studies 104 and 111) evaluating an investigational
once-daily single tablet regimen containing tenofovir alafenamide
(TAF) for the treatment of HIV-1 infection in treatment-naïve
adults. TAF is a novel nucleotide reverse transcriptase inhibitor
that has demonstrated high antiviral efficacy at a dose 10 times
lower than Gilead’s Viread, as well as improved renal and bone
laboratory parameters, in clinical trials.
- Positive results from a preclinical
study conducted in collaboration with researchers at Beth Israel
Deaconess Medical Center evaluating a proprietary investigational
oral TLR7 agonist and analogue of GS-9620 as part of an HIV
eradication strategy. Data demonstrated that treatment with the
TLR7 agonist induced transient plasma Simian Immunodeficiency Virus
(SIV) RNA, as well as reduced SIV DNA in virally suppressed rhesus
macaques given antiretroviral therapy (ART). In addition, the study
found that after discontinuation of ART, SIV viral loads were lower
among macaques that received the proprietary TLR7 agonist compared
to the placebo group.
Conference Call
At 4:30 p.m. Eastern Time today, Gilead's management will host a
conference call and a simultaneous webcast to discuss the company's
financial results for the first quarter 2015 as well as provide a
general business update. The live webcast of the call can be
accessed at the company's Investors page at www.gilead.com/investors. Please connect to the
company's website at least 15 minutes prior to the start of the
call to ensure adequate time for any software download that may be
required to listen to the webcast. Alternatively, please call
1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial
the conference ID 19520644 to access the call. Telephone replay
will be available approximately two hours following the call
through 11:59 p.m. Eastern Time, May 2, 2015. To access the replay,
please call 1-855-859-2056 (U.S.) or 1-404-537-3406 (international)
and dial the conference ID 19520644. The webcast will be archived
on www.gilead.com/investors for one
year.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company's mission is to advance the care of
patients suffering from life-threatening diseases. Gilead has
operations in more than 30 countries worldwide, with headquarters
in Foster City, California.
Non-GAAP Financial
Information
Gilead has presented certain financial information in accordance
with U.S. generally accepted accounting principles (GAAP) and also
on a non-GAAP basis. Management believes this non-GAAP information
is useful for investors, when considered in conjunction with
Gilead's GAAP financial statements, because management uses such
information internally for its operating, budgeting and financial
planning purposes. Non-GAAP information is not prepared under a
comprehensive set of accounting rules and should only be used to
supplement an understanding of Gilead's operating results as
reported under GAAP. A reconciliation between GAAP and non-GAAP
financial information is provided in the tables on pages 6 and
7.
Forward-looking
Statements
Statements included in this press release that are not
historical in nature are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Gilead cautions readers that forward-looking statements are subject
to certain risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include:
Gilead's ability to achieve its anticipated full year 2015
financial results; Gilead's ability to sustain growth in revenues
for its antiviral and other programs; availability of funding for
state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by federal and state grant cycles which
may not mirror patient demand and may cause fluctuations in
Gilead's earnings; the possibility of unfavorable results from
clinical trials involving sofosbuvir-containing products, tenofovir
alafenamide, including in combination with other products, and
GS-9620; Gilead's ability to initiate clinical trials in its
currently anticipated timeframes; the levels of inventory held by
wholesalers and retailers which may cause fluctuations in Gilead's
earnings; Gilead's ability to submit new drug applications for new
product candidates in the timelines currently anticipated; Gilead's
ability to receive regulatory approvals in a timely manner or at
all, for new and current products, including fixed-dose combination
of ledipasvir and sofosbuvir in Japan; Gilead's ability to
successfully commercialize its products; the risk that physicians
and patients may not see advantages of these products over other
therapies and may therefore be reluctant to prescribe the products;
the risk that estimates of patients with HCV or anticipated patient
demand may not be accurate; the risk that private and public payers
may be reluctant to provide, or continue to provide, coverage or
reimbursement for new products, including Sovaldi and Harvoni;
Gilead's ability to successfully develop its oncology,
inflammation, cardiovascular and respiratory programs, including
the compounds purchased from Phenex Pharmaceuticals AG; safety and
efficacy data from clinical studies may not warrant further
development of Gilead's product candidates, including GS-9620; the
potential for additional austerity measures in European countries
that may increase the amount of discount required on Gilead's
products; Gilead's ability to complete its share repurchase program
due to changes in its stock price, corporate or other market
conditions; Gilead’s ability to pay dividends under its dividend
program and the risk that its Board of Directors may reduce the
amount of the dividend; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency
exchange impact on Gilead's future revenues and pre-tax earnings;
and other risks identified from time to time in Gilead's reports
filed with the U.S. Securities and Exchange Commission (SEC). In
addition, Gilead makes estimates and judgments that affect the
reported amounts of assets, liabilities, revenues and expenses and
related disclosures. Gilead bases its estimates on historical
experience and on various other market specific and other relevant
assumptions that it believes to be reasonable under the
circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that
are not readily apparent from other sources. Actual results may
differ significantly from these estimates. You are urged to
consider statements that include the words may, will, would, could,
should, might, believes, estimates, projects, potential, expects,
plans, anticipates, intends, continues, forecast, designed, goal,
or the negative of those words or other comparable words to be
uncertain and forward-looking. Gilead directs readers to its press
releases, Annual Report on Form 10-K for the year ended December
31, 2014 and other subsequent disclosure documents filed with the
SEC. Gilead claims the protection of the Safe Harbor contained in
the Private Securities Litigation Reform Act of 1995 for
forward-looking statements.
All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.
Gilead owns or has rights to various trademarks, copyrights and
trade names used in our business, including the following: GILEAD®,
GILEAD SCIENCES®, HARVONI®, SOVALDI®, TRUVADA®, STRIBILD®,
COMPLERA®, EVIPLERA®, VIREAD®, LETAIRIS®, RANEXA®, AMBISOME®,
ZYDELIG®, EMTRIVA®, TYBOST®, HEPSERA®, VITEKTA®, CAYSTON®,
VOLIBRIS®, and RAPISCAN®.
ATRIPLA® is a registered trademark belonging to Bristol-Myers
Squibb & Gilead Sciences, LLC. LEXISCAN® is a registered
trademark belonging to Astellas U.S. LLC. MACUGEN® is a registered
trademark belonging to Eyetech, Inc. SUSTIVA® is a registered
trademark of Bristol-Myers Squibb Pharma Company. TAMIFLU® is a
registered trademark belonging to Hoffmann-La Roche Inc.
For more information on Gilead Sciences, Inc.,
please visit www.gilead.com or call the Gilead Public Affairs
Department at 1-800-GILEAD-5 (1-800-445-3235).
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF
INCOME
(unaudited)
(in millions, except per share
amounts)
Three Months Ended March 31, 2015
2014 Revenues: Product sales $ 7,405 $ 4,871 Royalty,
contract and other revenues 189 128 Total revenues
7,594 4,999 Costs and expenses: Cost of goods sold
882 813 Research and development expenses 696 595 Selling, general
and administrative expenses 645 548 Total costs and
expenses 2,223 1,956 Income from operations 5,371
3,043 Interest expense (153 ) (76 ) Other income (expense), net 21
(18 ) Income before provision for income taxes 5,239 2,949
Provision for income taxes 907 726 Net income 4,332
2,223 Net loss attributable to noncontrolling interest 1 4
Net income attributable to Gilead $ 4,333 $ 2,227
Net income per share attributable to Gilead common
stockholders - basic $ 2.91 $ 1.45 Net income per
share attributable to Gilead common stockholders - diluted $ 2.76
$ 1.33 Shares used in per share calculation - basic
1,488 1,537 Shares used in per share calculation -
diluted 1,569 1,680
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP
FINANCIAL INFORMATION*
(unaudited)
(in millions, except percentages and
per share amounts)
Three Months Ended March 31, 2015
2014 Cost of goods sold reconciliation: GAAP
cost of goods sold $ 882 $ 813 Stock-based compensation expenses (3
) (3 ) Acquisition related-amortization of purchased intangibles
(206 ) (199 ) Variable interest entity consolidated costs (2) 1
— Non-GAAP cost of goods sold $ 674 $ 611
Product gross margin reconciliation: GAAP
product gross margin 88.1 % 83.3 % Stock-based compensation
expenses — % 0.1 % Acquisition related-amortization of purchased
intangibles 2.8 % 4.1 % Non-GAAP product gross margin(1) 90.9 %
87.4 %
Research and development expenses
reconciliation: GAAP research and development expenses $ 696 $
595 Stock-based compensation expenses (42 ) (34 ) Acquisition
related-contingent consideration remeasurement (3 ) (3 ) Non-GAAP
research and development expenses $ 651 $ 558
Selling, general and administrative expenses reconciliation:
GAAP selling, general and administrative expenses $ 645 $ 548
Stock-based compensation expenses (47 ) (46 ) Restructuring
expenses 2 — Acquisition related-amortization of purchased
intangibles — (2 ) Non-GAAP selling, general and
administrative expenses $ 600 $ 500
Operating margin reconciliation: GAAP operating margin 70.7
% 60.9 % Stock-based compensation expenses 1.2 % 1.6 % Acquisition
related-amortization of purchased intangibles 2.7 % 4.0 %
Acquisition related-contingent consideration remeasurement — % 0.1
% Non-GAAP operating margin(1) 74.7 % 66.6 %
Other income
(expense) reconciliation: GAAP other income (expense), net $ 21
$ (18 ) Acquisition related-transaction costs — (2 )
Non-GAAP other income (expense), net $ 21 $ (20 )
Note: (1) Amounts may not sum due to rounding (2) Consolidation of
a contract manufacturer * Immaterial amounts are not presented in
the tables above
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP
FINANCIAL INFORMATION - (Continued)*
(unaudited)
(in millions, except percentages and
per share amounts)
Three Months Ended March 31, 2015
2014 Effective tax rate reconciliation: GAAP
effective tax rate 17.3 % 24.6
%
Acquisition related-amortization of purchased intangibles (0.4
)%
(1.4
)%
Non-GAAP effective tax rate(1) 16.9 % 23.2
%
Net income attributable to Gilead reconciliation:
GAAP net income attributable to Gilead $ 4,333 $ 2,227 Stock-based
compensation expenses 69 64 Restructuring expenses (2 ) —
Acquisition related transaction costs —
(1
)
Acquisition related-amortization of purchased intangibles 201 195
Acquisition related-contingent consideration remeasurement 3
3 Non-GAAP net income attributable to Gilead $ 4,604
$ 2,488
Diluted earnings per share
reconciliation: GAAP diluted earnings per share $ 2.76 $ 1.33
Stock-based compensation expenses 0.04 0.04 Acquisition
related-amortization of purchased intangibles 0.13 0.12
Non-GAAP diluted earnings per share(1) $ 2.94 $ 1.48
Shares used in per share calculation (diluted)
reconciliation: GAAP shares used in per share calculation
(diluted) 1,569 1,680 Share impact of current stock-based
compensation rules (1 ) (1 ) Non-GAAP shares used in per share
calculation (diluted) 1,568 1,679
Non-GAAP
adjustment summary: Cost of goods sold adjustments $ 208 $ 202
Research and development expenses adjustments 45 37 Selling,
general and administrative expenses adjustments 45 48 Other income
(expense) adjustments — (2 ) Total non-GAAP adjustments
before tax 298 285 Income tax effect (28 ) (24 ) Less: variable
interest entity consolidated costs (2) 1 — Total
non-GAAP adjustments after tax attributable to Gilead $ 271
$ 261 Note: (1) Amounts may not sum due to rounding
(2) Consolidation of a contract manufacturer * Immaterial amounts
are not presented in the tables above
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE
SHEETS
(unaudited)
(in millions)
March 31, December 31, 2015
2014(1) Cash, cash equivalents and marketable
securities $ 14,514 $ 11,726 Accounts receivable, net 4,835 4,635
Inventories 1,908 1,386 Property, plant and equipment, net 1,765
1,674 Intangible assets, net 10,867 11,073 Goodwill 1,172 1,172
Other assets 3,260 2,998 Total assets $ 38,321 $
34,664 Current liabilities $ 7,428 $ 5,761 Long-term
liabilities 13,294 13,069 Equity component of currently redeemable
convertible notes 11 15 Stockholders’ equity(2) 17,588
15,819 Total liabilities and stockholders’ equity $ 38,321 $
34,664 (1) Derived from the audited consolidated financial
statements as of December 31, 2014. (2) As of March 31, 2015, there
were 1,477 million shares of common stock issued and outstanding.
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
(in millions)
Three Months Ended March 31, 2015
2014 Antiviral products: Harvoni – U.S. $ 3,016 $ —
Harvoni – Europe 477 — Harvoni – Other International 86 —
3,579 — Sovaldi – U.S. 421 2,098 Sovaldi – Europe 483
163 Sovaldi – Other International 68 13 972 2,274
Truvada – U.S. 409 368 Truvada – Europe 301 323 Truvada –
Other International 61 69 771 760 Atripla –
U.S. 494 490 Atripla – Europe 194 237 Atripla – Other International
46 53 734 780 Stribild – U.S. 282 187 Stribild
– Europe 61 24 Stribild – Other International 13 4 356
215 Complera / Eviplera – U.S. 163 131 Complera /
Eviplera – Europe 145 109 Complera / Eviplera – Other International
12 11 320 251 Viread – U.S. 100 81 Viread –
Europe 80 84 Viread – Other International 54 46 234
211 Other Antiviral – U.S. 14 7 Other Antiviral – Europe 7 9
Other Antiviral – Other International 1 2 22 18
Total antiviral products – U.S. 4,899 3,362 Total antiviral
products – Europe 1,748 949 Total antiviral products – Other
International 341 198 6,988 4,509 Other products:
Letairis 151 123 Ranexa 117 111 AmBisome 85 92 Zydelig 26 — Other
38 36 417 362 Total product sales $ 7,405
$ 4,871
Gilead Sciences, Inc.InvestorsRobin
Washington, 650-522-5688Patrick O'Brien,
650-522-1936MediaAmy Flood, 650-522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024